SDC1 and urinary bladder cancer: Simultaneous loss of syndecan-1 expression in tumour cells and its overexpression in high-stage and high-grade bladder cancer patients serum suggest the importance of syndecan-1 in tumour progression; therefore, this molecule could be a new therapeutic target in human urinary bladder cancer [158].